During this desensitization 300 mg acetylsalicylic acid (ASA) were added to the rest of the patient's premedication. **At this point the patient had received a total of 3 doses of omalizumab (300mg each).
Omalizumab, an anti-IgE monoclonal antibody, is used as an adjuvant in hymenoptera venom immunotherapy and in induction of oral tolerance in food allergy [1, 2] .Few cases of its use in platindesensitizationshave been reported, and each one employs a different regimen [3] [4] [5] .We present a case of successful oxaliplatin desensitization achieved after a single initial dose of omalizumab, in a patient with elevated IgE levels upon oxaliplatin reintroduction, and after severe hypersensitivity reactions(HSRs) during previous desensitization attempts.
A 57-year-old patient diagnosed with metastatic sigmoid adenocarcinoma was initially treated in 2014 with nine cycles of folinate, oxaliplatin and 5-fluorouracil. In 2016 he received eight cycles of folinate, irinotecan and 5-fluorouracil. Later that year his treatment was substituted for gemcitabine, oxaliplatin and bevacizumab. He tolerated one cycle of this regimen.During the second cycle, after receiving gemcitabine and while receiving oxaliplatin, he experienced generalized erythema, cough, dyspnea and oxygen desaturation. Intradermal testing to oxaliplatin (0.5 mg/ml) was positive(negative prick test, 5mg/ml). Prick (38mg/mL) and intradermal (0.38 mg/ml)tests to gemcitabine were negative. Oxaliplatin was substituted with irinotecan while maintaining gemcitabine and bevacizumab. He tolerated 3 cycles of this new regimen. During the fourth cycle, however, while receiving irinotecan, he presented with anaphylaxis (facial erythema, dyspnea and pharyngeal pruritus).Intradermal testing to irinotecan (2 mg/ml) was positive(negative prick test, 20 mg/mL).
In 2018, due to cancer progression, the patient was assigned treatment with folinate, oxaliplatin, 5-fluorouracil and bevacizumab. A first 12-step desensitization [6] to oxaliplatinwas completed without adverse symptoms. Premedicationwith acetylsalicylic acid (ASA) was avoided for this desensitization, due to a history of angioedema possibly related to this drug (he tolerated other nonsteroidal antiinflammatory drugs). He received oral premedication with10-mgmontelukast two days before administration, and with 10-mg montelukastand300-mg ranitidineon the day of administration. The oncology department added intravenous premedication with20-mg dexamethasone and5-mg dexchlorpheniramine, and1-g oral acetaminophen.
During the second desensitization, however, the patient experienced facial erythema, wheezing, dyspnea,oxygendesaturation(89%), tachycardia(110 bpm), and hypotension(80/50 mmHg)during step 10 (7-mg threshold dose). Forty-eight hours later, a new, 16-stepattempt failed due to facial erythema, cough and oxygen desaturation(89%) during step 14 (7-mg threshold).
Retrospectively analyzed serum samples from 24 hours before and immediately after the first unsuccessful desensitization showed total IgE levels of 6900 and 7410 kU/L, respectively. Serum tryptase samples were drawn immediately after the 12-step desensitization (2.03 ug/L), and immediately and 2 hours after the 16-step desensitization (<1.00 ug/L in both cases).Baseline tryptase levels were of 1.37 ug/L, and eosinophil counts were normal. Skin testing to a standard allergen battery and stool parasites tests were negative. He reported no previous history of allergic disease (atopic dermatitis, rhinoconjunctivitis, asthma), alcohol intake or tuberculosis. A provocation test with 300mg of ASA was completed without adverse symptoms.
We administered a single, 300 mg dose of subcutaneous omalizumab 19 days before re-attempting desensitization. We employed an 18-step protocol, and 300 mg of ASA were added to the premedication regimen. He experienced facial and upperextremity erythema during the fifteenth step (cumulative oxaliplatin dose: 7.2 mg) that J Investig Allergol Clin Immunol 2020; Vol. 30(4) © 2020 Esmon Publicidad doi: 10.18176/jiaci.0496 responded quickly to intravenous dexclorpheniramine. Desensitization was re-started 30 minutes later by repeating the previous step and resuming the protocol. There were no new symptoms. This procedure was repeated every two weeks for four subsequent cycles, using 300 mg of omalizumab two weeks before each cycle. No new hypersensitivity events occurred, and the patient achieved clinical stability of cancer.
Variation in total IgE levels is shown in Figure 1 . (2019) employed a single 300 mg dose of omalizumab one week before desensitization [5] .
To the best of our knowledge, initial total IgE levels in these reports were not elevated. In our case, however, total IgE levels were consistently high before the first severe HSR, after re-exposure to oxaliplatin. We cannot confirm whether this IgE profile occurred due tospecific IgE against oxaliplatin or to underlying systemic causes, but itdefined our patient as a challenging case for desensitization.Regardless, omalizumab was effective as an adjuvant after a single dose, and repeated use resulted in tolerance of all subsequent cycles.Considering this may prove useful when developing omalizumab protocols in suchsituations.
It is important to mention that, in our case, factors other than omalizumab may have led to a favorable outcome. Protocol extension and ASA were added concomitantly to omalizumab. The use of longer protocols has been described as a J Investig Allergol Clin Immunol 2020; Vol. 30(4) © 2020 Esmon Publicidad doi: 10.18176/jiaci.0496 means to achieve desensitization tolerance [7] ,and this may have aided in the final result. Breslow et al. described the efficacy of pretreatment with ASA and montelukast in lessening the severity and thefrequency of HSRs to chemotherapy during desensitization [8] . There is little further evidence proving this guarding effect, but we cannot rule out its contribution in our patient. Further studies are necessary in patients with a history of failed desensitizations despite protocol modification and complete premedication regimens.
Our patient's total IgE profile, however, leads us to believe that tolerance without anti-IgE treatment would have been difficult. Observed variations in total IgE levels are worth noting (Figure 1 ). Prior to receiving anti-IgE treatment, levels had declined from 7410 to 4690 kU/L in a two-week periodwithout significant interventions, possibly in part due tointra-test variation [9] . Three weeks after the initial dose of omalizumab, we observed a further decline in total IgE from 4690 to 2664 kU/L, similar to that observed by Ojaimi et al. 4 Finally, total IgE levels had descended to 575 kU/L five months after receiving the last dose of omalizumab.This clear reduction may partially explain the observed oxaliplatin desensitization [10] .
In cases of advanced cancer where delay in treatment may impair prognosis, time-sparing solutions after unsuccessful desensitizations are clearly beneficial. We report a case of successful platin desensitization after a single dose of omalizumab, in a patient with a challenging IgE profile. Our outcomemay indicate that the use of singledose anti-IgE regimens -along with protocol modification-could be as effective as regimens that employ multiple doses before reattempting desensitization. This seems to be true even in patients with elevated total IgE and a history of repeatedly failed desensitization attempts.
